Related Experiment Videos
[Antithrombotic therapy and follow-up of peripheral arterial occlusive disease]
1Universitätsklinikum Frankfurt am Main.
In patients with arterial occlusive disease the following antithrombotic drugs are used to prevent new arterial thromboses: Unfractionated heparin (UFH) and low molecular weight heparins (LMWH): UFH is frequently used perioperatively in patients with vascular reconstructions and after peripheral percutaneous transluminal angioplasty (PTA). Only one study on the longterm use of a LMWH after operative revascularization has been published, where LMWH led to an increased patency rate in comparison to acetylsalicylic acid + dipyridamol. Vitamin-K-antagonists were effective in the prevention of new vascular occlusions in studies published in the 1970ies. Platelet function inhibitors (aspirine, ticlopidine and clopidogrel): Aspirine reduced reocclusions after vascular surgery and PTA. Ticlopidine was effective in the Swedish Ticlopidine-Multicenter-Trial in the prevention of ischemic heart disease and also reduced the need for vascular surgery. In the CAPRIE-study clopidogrel reduced myocardial infarctions in patients with peripheral arterial disease in comparison to aspirine.
In patients with arterial occlusive disease the following antithrombotic drugs are used to prevent new arterial thromboses: Unfractionated heparin (UFH) and low molecular weight heparins (LMWH): UFH is frequently used perioperatively in patients with vascular reconstructions and after peripheral percutaneous transluminal angioplasty (PTA). Only one study on the longterm use of a LMWH after operative revascularization has been published, where LMWH led to an increased patency rate in comparison to acetylsalicylic acid + dipyridamol. Vitamin-K-antagonists were effective in the prevention of new vascular occlusions in studies published in the 1970ies. Platelet function inhibitors (aspirine, ticlopidine and clopidogrel): Aspirine reduced reocclusions after vascular surgery and PTA. Ticlopidine was effective in the Swedish Ticlopidine-Multicenter-Trial in the prevention of ischemic heart disease and also reduced the need for vascular surgery. In the CAPRIE-study clopidogrel reduced myocardial infarctions in patients with peripheral arterial disease in comparison to aspirine.